Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Clin Cancer Res · 2023 · PMC10570675 · PMID 37581616

Europe PMC DOI

hedged sentences

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significanceP = 0.11not close (p > 0.1)

3 (7%) of 42], although this did not reach statistical significance (multiple comparison adjusted P = 0.11, test for interaction; ref. 11 ).

also in 111,027 other papers

a nonsignificant trendno p-value reported

There was a nonsignificant trend toward PFS improvement in PCC-treated patients with MAPK pathway alterations compared with those without (HR, 0.82; 95% CI, 0.43–1.59).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.